A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

ConclusionsS-1 as a third- or fourth-line therapy for wild-typeEGFR NSCLC showed numerically better clinical outcomes than erlotinib.Clinical trial registration no.UMIN000005308.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research